CryptoMedix
CryptoMedix Inc. is a biotech company focused on immuno-oncology and tumor microenvironment (TME) therapies. They develop therapeutic antibodies that promote cytotoxic T-cell activity and inhibit tumor-suppressive macrophages, with a focus on enhancing the efficacy of PD(L)1 immune-checkpoint inhibitors. Despite being in early pre-clinical stages, the company is advancing scientific research and seeking partnerships and funding to progress.
Industries
Nr. of Employees
small (1-50)
CryptoMedix
Harpswell, Maine, United States, North America
Products
Therapeutic antibody candidate with systemic TME activity
Preclinical antibody candidate that promotes cytotoxic T-cell activity and inhibits tumor-supportive macrophages in the TME; evaluated for synergy with immune-checkpoint inhibitors.
TME-retained antibody candidate optimized for conjugation
Preclinical antibody candidate characterized by retention in the TME, suitable for development as an antibody-drug conjugate (ADC) or radionuclide conjugate while exhibiting intrinsic anti-tumor activity.
Therapeutic antibody candidate with systemic TME activity
Preclinical antibody candidate that promotes cytotoxic T-cell activity and inhibits tumor-supportive macrophages in the TME; evaluated for synergy with immune-checkpoint inhibitors.
TME-retained antibody candidate optimized for conjugation
Preclinical antibody candidate characterized by retention in the TME, suitable for development as an antibody-drug conjugate (ADC) or radionuclide conjugate while exhibiting intrinsic anti-tumor activity.
Services
Targeted outreach and discussions with venture capital, biotech, and pharmaceutical partners to identify development collaborations.
Engagement of external oncology and immunology experts to advise on program strategy and development.
Activities to secure development funding via investor contributions and grant applications.
Targeted outreach and discussions with venture capital, biotech, and pharmaceutical partners to identify development collaborations.
Engagement of external oncology and immunology experts to advise on program strategy and development.
Activities to secure development funding via investor contributions and grant applications.
Expertise Areas
- Immuno-oncology
- Tumor microenvironment targeting
- Therapeutic antibody engineering
- Antibody-drug conjugate and radionuclide targeting
Key Technologies
- Therapeutic monoclonal antibody design
- Proteasome-mediated target degradation
- Immune-checkpoint targeting (PD-L1, LAG-3)
- Antibody-drug conjugate (ADC) development
News & Updates
Two newly issued U.S. patents
The company has secured two new patents related to their immuno-oncology technology, emphasizing their novel mechanism of action involving proteasome-mediated degradation of PDL1.
Two newly issued U.S. patents
The company has secured two new patents related to their immuno-oncology technology, emphasizing their novel mechanism of action involving proteasome-mediated degradation of PDL1.